



Nalidixic Acid [HRP] (DAG1246)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview	Nalidixic Acid, HRP conjugate
Antigen Description	The quinolones are antimicrobial agents that inhibit the activity of DNA gyrase and topoisomerase IV. The fluoroquinolones are divided into 2 groups, based on antimicrobial spectrum and pharmacology: The quinolones are active against a broad range of bacteria including Enterobacteriaceae, Streptococci, Chlamydia and Legionella. Older quinolones such as ciprofloxacin and norfloxacin have poor activity against streptococci and anaerobes. The quinolones are widely distributed to most body fluids and tissues. They are variably metabolised in the liver and excreted in the urine. Quinolones are used extensively in veterinary medicine and their use in food producing animals could result in potentially harmful concentrations in tissue, organs and milk. The potential risk is reduced by withdrawal of the drug for a fixed period before slaughter, although residual levels may remain.
Nature	Synthetic
Expression System	N/A
Species	N/A
Conjugate	HRP
Procedure	None
Format	Concentrate
Size	0.5 ml
Preservative	None
Storage	2-8°C short term, -20°C long term
Warnings	PLEASE note that this product is intended for research use only; not for diagnostic or clinical use.

BACKGROUND

Introduction	Nalidixic acid (tradenames Nevigramon, Neggram, Wintomylon and WIN 18,320) is the first of the synthetic quinolone antibiotics. In the technical sense, it is a naphthyridone, not a quinolone: its ring structure is a 1,8-naphthyridine nucleus that contains two nitrogen atoms, unlike quinoline, which has a single nitrogen atom.
Keywords	Nalidixic Acid